Figshareopen access
Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada
medicine, pharmacology, ecology, science policy, biological sciences not elsewhere classified, parkinson’s disease, costs, indirect costs
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 384363
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.